{"prompt": "['1. STUDY OBJECTIVE', '1.1. Safety run-in phases objectives', 'Validate the good tolerability of treatments combination in 2 steps:', '- 1st step: treated 5 patients with FOLFIRI (irinotecan at 180 mg/m\u00b2) + durvalumab', '-', '2nd step: randomized 6 patients between FOLFIRI (irinotecan at 180 mg/m\u00b2) + durvalumab versus', 'FOLFIRI (irinotecan at 150 mg/m\u00b2) + durvalumab + tremelimumab (3 patients per arm)', 'Patients will be treated in 5 expert centers with a huge experience in the use of immune checkpoints inhibitors.', 'Inclusions will be stopped at each step for safety analyses.', '1.2. Primary objective of phase II only', 'Percentage of patients alive and without progression at 4 months of FOLFIRI plus durvalumab versus FOLFIRI', 'plus durvalumab plus tremelimumab in patients with advanced-stage gastric or gastro-oesophageal junction', 'adenocarcinoma and who progressed after a first line chemotherapy (based on RECIST 1.1 rating scale', 'evaluated by the investigator).', '1.3. Secondary objectives for phase II study', '-', 'Percentage of patients alive and without progression at 4 months according to centralized review', '-', 'Overall survival (OS)', '-', 'Time to strategy failure', '-', 'Safety profile', '-', 'Quality of life (QoL)', '-', 'Time to progression (TTP), the progression-free survival (median PFS), the best objective response rate', '(BRR) and disease control rate (DCR) according to the investigator and centralized review (according', 'RECIST V1.1 and iRECIST criteria)', '-', 'Efficacy endpoints (OS, PFS, TTP, BRR and DCR) according to the expression PD-L1 and others', 'biomarkers (see biological study)', 'Phase II only: Ancillary biological studies (optional)', 'Blood and tumor samples will be collected in all patients in order to allow translational research projects (Centre', 'de Ressource Biologique EPIGENETEC, UMR-S 1147, Paris, France, Headed by Prof. Pierre Laurent-Puig):', '- Biomarkers analysis (for more details see \"ancillary studies\" - Appendix 2): microsatellite instability, immune', 'response/immune score, circulating tumor DNA, tumor mutation load, gastric molecular sub-groups, expression', 'and/or amplification of PD-L1 and PD-L2).', '- Stool samples will be collected prospectively in all patients in order to allow analysis of microbiota (16S', 'rRNA to identification of bacteria composing the intestinal microbiota of patients).', '2. PATIENT SELECTION ON REGISTRATION/RANDOMIZATION', 'Inclusion and non-inclusion criteria are the same for the safety run-in phases and the randomized phase II trial.', '2.1. Inclusion criteria', '-', 'Age > 18 years.', '-', 'Body weight > 30kg.', '-', 'Histologically proven advanced-stage unresectable adenocarcinoma of the stomach or the GEJ (Siewert', 'II or III).', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 14 de 123']['-', 'Known MSS/MSI status or tumor tissue available (frozen or paraffin-embedded, primary tumors or', 'metastases) in order to allow determination of MSS/MSI status. The investigator needs to ensure that', 'tumor tissues will be sent after patient randomization.', '-', 'Failure to platinium-based 1st line therapy with or without trastuzumab or early recurrent disease after', 'surgery with neo-adjuvant and/or adjuvant platinium-based chemotherapy (within 6 months of the end', 'of chemotherapy) or progression during neo-adjuvant and/or adjuvant platinium-based chemotherapy.', '-', 'Eligible for a second-line treatment with irinotecan and 5-FU.', '-', 'Measurable or non-measurable lesion according to the Response Evaluation Criteria in Solid Tumors', '(RECIST 1.1).', '-', 'Eastern Cooperative Oncology Group (ECOG) performance status 0-1.', '-', 'Adequate organ function: ANC > 1.5 X 109/L, haemoglobin > 9 g/dL, platelets > 100 x 109/L, AST/ALT', '3 x ULN (< 5 X ULN in case of liver metastase(s)) GGT 3 x ULN (< 5 x ULN in case of liver', 'metastase(s)), bilirubin VI 1.5 X ULN, creatinin clearance > 40 mL/min (MDRD).', 'Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-', 'menopausal patients.', '-', 'Man and woman who childbearing potential agrees to use two methods (one for the patient and one for', 'the partner) of medically acceptable forms of contraception during the study and for 6 months after the', 'last treatment intake.', 'Patient is able to understand, sign, and date the written informed consent form at the screening visit', 'prior to any protocol-specific procedures performed.', '2.2. Non-inclusion criteria', '-', 'Concurrent enrolment in another clinical study - unless it is an observational study or during the follow-', 'up period of an interventional study.', '-', 'Receipt of the last dose of anticancer therapy < 2 weeks prior to the first dose of study drug.', '-', 'Radiotherapy within 4 weeks prior to the first dose of treatment.', '-', 'History of chronic inflammatory bowel disease (IBD).', '-', 'Current or prior bowel obstruction within 28 days before the first dose of study drugs.', '-', 'Any unresolved significant toxicity NCI CTCAE v4.0 > grade 2 from previous anticancer therapy', '(excepted neuropathy and alopecia).', '-', 'Concurrent use of hormonal therapy for non-cancer-related conditions is acceptable', '-', 'Major surgical procedure (e.g. exploratory laparoscopy is not considered as a major surgical procedure)', 'within 28 days prior to the first dose of treatment.', '-', 'Prior allogeneic bone marrow transplantation or prior solid organ transplantation.', '-', 'Active or prior documented autoimmune or inflammatory disorders (patients with alopecia, vitiligo,', 'controlled hypo or hyperthyroidism, any chronic skin condition not requiring immunosuppressant', 'therapy are eligible). Patients without active disease in the last 5 years may be included.', 'Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic', 'congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia,', 'interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or', 'psychiatric illness/social situations that would limit compliance with study requirement, substantially', 'increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.', '-', 'Severe cardiac disorders within 6 months.', '-', 'Severe liver dysfunction', 'History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia, or evidence', 'of active pneumonitis on screening chest CT-scan.', 'History of leptomeningeal carcinomatosis or symptomatic or untreated brain metastase(s). Patients whose brain', 'metastase(s) have been treated may participate if any neurologic symptoms that developed either as a result of the', 'brain metastases or their treatment are resolved or be stable either, without the use of steroids, or are stable on a', 'steroid dose of <10mg/day of prednisone or its equivalent for at least 14 days prior to the start of treatment.', '-', '-', 'Positive test for HIV, active hepatitis B or hepatitis C, active tuberculosis.', '-', 'History of active primary immunodeficiency', '-', 'Current or prior use of immunosuppressive medication within 14 days before the first dose of study', 'drugs (excepted: intranasal, inhaled, topical steroids or local steroid injection -at physiologic dose does', 'not exceed 10 mg/day of prednisone or its equivalent - steroids as premedication for hypersensitivity', 'reactions).', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 15 de 123']\n\n###\n\n", "completion": "END"}